BioPharma Dive

18.1K posts

BioPharma Dive

@BioPharmaDive

We provide in-depth insight into the most significant news and trends shaping biotech and pharma. Sign up here: dive.pub/_BD9

Washington, D.C.

BioPharmaDive.com

Joined July 2013

13.9K Followers

RepliesReplies RepostsReposts MediaMedia

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone

or

Log in with username or email

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.

Pinned
BioPharma Dive
@BioPharmaDive
Jan 23
Get the latest biotech & pharma intel in your inbox for free. Our newsletters cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. Sign up today:
biopharmadive.com
BioPharma Dive Newsletter
Sign up for BioPharma Dive: The free email newsletter covering the top news and trends for biotech and pharma industry leaders.
BioPharma Dive
@BioPharmaDive
20h
Rapport’s epilepsy drug finds surprising success in bipolar trial biopharmadive.com/news/rapport-b… $RAPP by @realJacobBell
Rapport’s epilepsy drug finds surprising success in bipolar trial
From biopharmadive.com
2
BioPharma Dive
@BioPharmaDive
21h
Most new drugs are still too costly at launch, ICER says biopharmadive.com/news/icer-new-… @ByJonGardner
Most new drugs are still too costly at launch, ICER says
From biopharmadive.com
BioPharma Dive
@BioPharmaDive
Oct 19
News Roundup: Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
From biopharmadive.com
BioPharma Dive
@BioPharmaDive
Oct 19
Disc’s once-spurned rare disease drug to get a second chance at approval biopharmadive.com/news/Disc-bito… $IRON by @Lilah_Alvarado
Disc’s once-spurned rare disease drug to get a second chance at approval
From biopharmadive.com
2

Rapport Therapeutics Inc